Display options
Cite
Das B, Jain N, Mallick B. piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. Commun Biol. 2021;4(1):1312doi: 10.1038/s42003-021-02844-1.
Das, B., Jain, N., & Mallick, B. (2021). piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. Communications biology, 4(1), 1312. https://doi.org/10.1038/s42003-021-02844-1
Das, Basudeb, et al. "piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair." Communications biology vol. 4,1 (2021): 1312. doi: https://doi.org/10.1038/s42003-021-02844-1
Das B, Jain N, Mallick B. piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. Commun Biol. 2021 Nov 19;4(1):1312. doi: 10.1038/s42003-021-02844-1. PMID: 34799689; PMCID: PMC8605029.
Copy Download .nbib Format: NLM
Share it on

Commun Biol. 2021 Nov 19;4(1):1312. doi: 10.1038/s42003-021-02844-1.

piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair.

Communications biology

Basudeb Das, Neha Jain, Bibekanand Mallick

Affiliations

  1. RNAi and Functional Genomics Lab, Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India.
  2. RNAi and Functional Genomics Lab, Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India. [email protected].

PMID: 34799689 PMCID: PMC8605029 DOI: 10.1038/s42003-021-02844-1

Abstract

Resistance to doxorubicin (DOX) is an obstacle to successful sarcoma treatment and a cause of tumor relapse, with the underlying molecular mechanism still unknown. PIWI-interacting RNAs (piRNAs) have been shown to enhance patient outcomes in cancers. However, there are few or no reports on piRNAs affecting chemotherapy in cancers, including fibrosarcoma. The current study aims to investigate the relationship between piR-39980 and DOX resistance and the underlying mechanisms. We reveal that piR-39980 is less expressed in DOX-resistant HT1080 (HT1080/DOX) fibrosarcoma cells. Our results show that inhibition of piR-39980 in parental HT1080 cells induces DOX resistance by attenuating intracellular DOX accumulation, DOX-induced apoptosis, and anti-proliferative effects. Its overexpression in HT1080/DOX cells, on the other hand, increases DOX sensitivity by promoting intracellular DOX accumulation, DNA damage, and apoptosis. The dual-luciferase reporter assay indicates that piR-39980 negatively regulates RRM2 and CYP1A2 via direct binding to their 3'UTRs. Furthermore, overexpressing RRM2 induces DOX resistance of HT1080 cells by rescuing DOX-induced DNA damage by promoting DNA repair, whereas CYP1A2 confers resistance by decreasing intracellular DOX accumulation, which piR-39980 restores. This study reveals that piR-39980 could reduce fibrosarcoma resistance to DOX by modulating RRM2 and CYP1A2, implying that piRNA can be used in combination with DOX.

© 2021. The Author(s).

References

  1. Cancer Metastasis Rev. 2020 Jun;39(2):567-575 - PubMed
  2. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S13-6 - PubMed
  3. Genes (Basel). 2016 Dec 20;7(12): - PubMed
  4. Methods Mol Biol. 2010;596:47-76 - PubMed
  5. Mol Cancer. 2018 Jan 30;17(1):16 - PubMed
  6. Lancet Oncol. 2014 Apr;15(4):415-23 - PubMed
  7. Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85 - PubMed
  8. Biosci Rep. 2019 May 7;39(5): - PubMed
  9. Cancer Metastasis Rev. 1987;6(3):261-81 - PubMed
  10. Am J Pathol. 2011 Feb;178(2):838-52 - PubMed
  11. Mol Cancer. 2019 Aug 9;18(1):123 - PubMed
  12. J Cell Physiol. 2020 Mar;235(3):2286-2299 - PubMed
  13. J Exp Clin Cancer Res. 2020 Nov 13;39(1):241 - PubMed
  14. Cancer Lett. 2012 Feb 1;315(1):12-7 - PubMed
  15. Int J Mol Med. 2016 Sep;38(3):927-36 - PubMed
  16. J Pharm Pharmacol. 2013 Feb;65(2):157-70 - PubMed
  17. Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85 - PubMed
  18. Clin Cancer Res. 2019 Jul 15;25(14):4480-4492 - PubMed
  19. Clin Chim Acta. 2011 Aug 17;412(17-18):1621-5 - PubMed
  20. Int J Oncol. 2013 May;42(5):1692-708 - PubMed
  21. Redox Biol. 2014 Jan 09;2:457-65 - PubMed
  22. J Clin Oncol. 1987 Jan;5(1):21-6 - PubMed
  23. Biomark Cancer. 2015 Dec 17;7:69-76 - PubMed
  24. Biol Cell. 2020 Mar;112(3):73-91 - PubMed
  25. Mol Ther Nucleic Acids. 2018 Sep 7;12:805-816 - PubMed
  26. Carcinogenesis. 2001 Dec;22(12):1931-7 - PubMed
  27. Biomed Pharmacother. 2021 Jan;133:110996 - PubMed
  28. Radiat Oncol. 2016 Oct 12;11(1):136 - PubMed
  29. Cancer Treat Res. 1991;57:209-32 - PubMed
  30. Oncogene. 2017 Jul 13;36(28):3986-4000 - PubMed
  31. Ann Transl Med. 2015 Dec;3(21):332 - PubMed
  32. Medicina (Kaunas). 2016;52(5):298-306 - PubMed
  33. Theranostics. 2018 Oct 6;8(19):5213-5230 - PubMed
  34. Oncotarget. 2016 Jul 19;7(29):46002-46013 - PubMed
  35. Front Genet. 2019 Feb 04;10:37 - PubMed
  36. Leukemia. 2015 Jan;29(1):196-206 - PubMed
  37. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 - PubMed
  38. Cancer Res. 1985 Sep;45(9):4091-6 - PubMed
  39. Genomics. 2013 Apr;101(4):213-20 - PubMed
  40. Biomed Rep. 2016 May;4(5):546-550 - PubMed
  41. Mol Carcinog. 2019 Mar;58(3):344-357 - PubMed
  42. Cancer. 1999 Jan 15;85(2):389-95 - PubMed
  43. Acta Pharm Sin B. 2017 Jan;7(1):38-51 - PubMed
  44. Noncoding RNA. 2019 Jan 16;5(1): - PubMed
  45. Oncotarget. 2017 May 23;8(21):34268-34282 - PubMed
  46. Front Pharmacol. 2019 Dec 06;10:1434 - PubMed
  47. Int J Mol Sci. 2020 May 02;21(9): - PubMed
  48. Front Oncol. 2014 Oct 31;4:306 - PubMed
  49. Pharmacol Rev. 2004 Jun;56(2):185-229 - PubMed
  50. J Hematol Oncol. 2019 Jun 7;12(1):55 - PubMed
  51. Mol Biotechnol. 2004 Mar;26(3):249-61 - PubMed
  52. FEBS Open Bio. 2020 Jun;10(6):1021-1030 - PubMed
  53. Drug Metab Rev. 2019 May;51(2):196-223 - PubMed
  54. Cancer. 2016 Oct;122(19):2952-60 - PubMed
  55. Ann Surg. 1982 Sep;196(3):305-15 - PubMed
  56. Oncol Rep. 2019 Aug;42(2):571-580 - PubMed
  57. Breast Cancer Res. 2004;6(4):R352-65 - PubMed
  58. Nat Protoc. 2006;1(1):23-9 - PubMed
  59. Nat Commun. 2017 Nov 10;8(1):1411 - PubMed
  60. Cardiovasc Res. 2011 May 1;90(2):305-14 - PubMed
  61. Cancer Sci. 2017 Sep;108(9):1746-1756 - PubMed
  62. Leukemia. 2010 Apr;24(4):679-86 - PubMed
  63. Mol Cancer. 2019 Jan 12;18(1):9 - PubMed
  64. Clin Sarcoma Res. 2012 Oct 04;2(1):14 - PubMed
  65. Cell Res. 2000 Sep;10(3):205-11 - PubMed
  66. Oncotarget. 2017 Jul 6;8(40):69086-69104 - PubMed
  67. Lancet. 1997 Dec 6;350(9092):1647-54 - PubMed
  68. Aging (Albany NY). 2019 Nov 13;11(21):9932-9946 - PubMed
  69. BMC Cancer. 2014 Sep 11;14:664 - PubMed
  70. Electrophoresis. 2012 Jan;33(2):366-9 - PubMed

Publication Types